Background: Cervical cancer is the second most prevalent cancer, both in terms of incidence and mortality, after breast cancer in regions with lower Human Development Index (HDI). However, it holds the distinction of being the most frequently diagnosed cancer in 28 countries and the primary cause of cancer-related deaths in 42 countries. The majority of these countries are located in Sub-Saharan Africa and South Eastern Asia. Cervical cancer stands as a prominent contributor to cancer-related fatalities in women. Based on estimates from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), there were approximately 529,000 new cases of cervical cancer worldwide in the year 2008. Methods: This study was done by retrieving information of 101 patients from records of Pathology Department in whom cervical malignancy was suspected by per speculum and per vaginal examination and confirmed by biopsyorhysterectomy. Standard streptavidin-biotin peroxidase method of IHC (immunohistochemical) was followed. Results: Increased expression of EGFR was seen in moderately differentiated squamous cell carcinoma than in adenocarcinoma and poorly differentiated SC carcinoma. P-value of EGFR over expression in MdSCC is <0.05, hence there is a significant association of EGFR over expression in MdSCC. Conclusion: The study revealed a noteworthy presence of the p16 biomarker in cervical cancer patients who were younger in age and at early stages of the disease. Consequently, the utilization of the p16 biomarker in screening or early diagnosis may contribute to improved prognosis for squamous cell carcinoma of the cervix.